Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

T Wakai; T Kanda; S Hirota; A Ohashi; Y Shirai; K Hatakeyama

doi:10.1038/sj.bjc.6601819

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

Br J Cancer. 2004 Jun 1;90(11):2059-61. doi: 10.1038/sj.bjc.6601819.

Authors

T Wakai¹, T Kanda, S Hirota, A Ohashi, Y Shirai, K Hatakeyama

Affiliation

¹ Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Niigata City 951-8510, Japan.

Abstract

Currently, there are no data on the secondary resistance of gastrointestinal stromal tumours to imatinib. Here, we report a case of metastatic gastrointestinal stromal tumour that relapsed during imatinib therapy. Mutation analysis showed that the imatinib-resistant liver tumour contained two c-kit mutations.

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / pharmacology*
Benzamides
DNA Mutational Analysis
Drug Resistance, Neoplasm / genetics
Gastrointestinal Neoplasms / drug therapy*
Gastrointestinal Neoplasms / genetics*
Gastrointestinal Neoplasms / pathology
Humans
Imatinib Mesylate
Male
Middle Aged
Piperazines / pharmacology
Proto-Oncogene Proteins c-kit / genetics*
Pyrimidines / pharmacology
Stromal Cells

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Proto-Oncogene Proteins c-kit